Has Fadi Estephan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $48,403 in general payments to Fadi Estephan, MD across 272 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Fadi Estephan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Fadi Estephan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Fadi Estephan, MD

Hematology & Oncology · Hutchinson, KSNPI 1013987924

Payments from drug & device makers

$48,403in general payments, 2019–2025

Across 272 payments — averaging $177.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Seagen Inc.$7K
AstraZeneca$7K
Exelixis Inc.$5K
Gilead$4K
Incyte Corporation$4K
Clovis Oncology, Inc.$3K
plus $17K from 40 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Seagen Inc.	11	$7,138
AstraZeneca	20	$7,087
Exelixis Inc.	15	$5,441
Gilead(2 entities)	13	$4,470
Incyte Corporation	6	$3,797
Clovis Oncology, Inc.	8	$3,415
Karyopharm Therapeutics Inc.	3	$3,399
Johnson & Johnson	8	$3,100
Bristol Myers Squibb	9	$1,584
Beigene USA, Inc.	1	$1,500
CTI Biopharma Corp.	1	$1,438
Epizyme, Inc.	1	$1,250
Geron Corporation	1	$1,200
Pfizer	36	$505
E.r. Squibb & Sons, L.L.C.	23	$373
Athenex Pharmaceutical Division, LLC	2	$350
Novartis	23	$342
AbbVie	12	$247
Astellas Pharma US Inc	8	$212
Array Biopharma Inc	4	$185
EMD Serono, Inc.	10	$166
Daiichi Sankyo Inc.	6	$142
Jazz Pharmaceuticals Inc.	6	$127
Bayer	3	$114
Amgen	7	$101
Comsort, Inc	1	$100
Merck	6	$86
Genentech USA, Inc.	5	$80
Eisai Inc.	2	$67
GSK	4	$60
Nevro Corp.	1	$48
Sanofi	2	$30
Recordati_rare_diseases_inc.	1	$24
Genmab U.S., Inc.	1	$24
Tersera Therapeutics LLC	1	$22
Sobi, Inc	1	$20
Kyowa Kirin, Inc.	1	$20
Regeneron Healthcare Solutions, Inc.	1	$19
Takeda Pharmaceuticals U.S.A., Inc.	1	$18
Agios Pharmaceuticals, Inc.	1	$16
Ipsen Biopharmaceuticals, Inc	1	$16
Springworks Therapeutics, Inc.	1	$16
Mirati Therapeutics, Inc.	1	$14
Sun Pharmaceutical Industries Inc.	1	$13
Verastem, Inc.	1	$13
AMAG Pharmaceuticals, Inc.	1	$12

How this compares

$48,403 in reported general payments places this provider in the 65th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas →

Medicare billing

Part B allowed, 2024

$2,537,559

Medicare patients

1,529

Services billed

220,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Hutchinson

Priyanka SharmaWestwood$18.5M
Anup Kumar Kasi Loknath KumarWestwood$15.3M
Marc HoffmannOverland Park$13.6M
Shaker DakhilWichita$11.2M
Sunil AbhyankarWestwood$5M
Joseph McGuirkKansas City$3.1M
Prakash NeupaneWestwood$2.7M
Joseph StilwillOverland Park$2.7M
Gary DoolittleWestwood$2.6M
Tara LinKansas City$2.2M

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →